Beam Therapeutics (BEAM) Competitors $26.04 +0.53 (+2.08%) (As of 09/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BEAM vs. NTLA, KYMR, REPL, EDIT, SGMO, EXEL, HALO, RGEN, RVMD, and KRYSShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Intellia Therapeutics (NTLA), Kymera Therapeutics (KYMR), Replimune Group (REPL), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Exelixis (EXEL), Halozyme Therapeutics (HALO), Repligen (RGEN), Revolution Medicines (RVMD), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector. Beam Therapeutics vs. Intellia Therapeutics Kymera Therapeutics Replimune Group Editas Medicine Sangamo Therapeutics Exelixis Halozyme Therapeutics Repligen Revolution Medicines Krystal Biotech Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher earnings and valuation, NTLA or BEAM? Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$45.97M48.13-$481.19M-$5.36-4.28Beam Therapeutics$352.57M6.08-$132.53M-$1.78-14.63 Is NTLA or BEAM more profitable? Intellia Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -40.56%. Beam Therapeutics' return on equity of -16.22% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -47.12% -38.62% Beam Therapeutics -40.56%-16.22%-10.65% Does the MarketBeat Community favor NTLA or BEAM? Intellia Therapeutics received 383 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 69.76% of users gave Intellia Therapeutics an outperform vote while only 52.27% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes42969.76% Underperform Votes18630.24% Beam TherapeuticsOutperform Votes4652.27% Underperform Votes4247.73% Does the media prefer NTLA or BEAM? In the previous week, Intellia Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for Intellia Therapeutics and 10 mentions for Beam Therapeutics. Intellia Therapeutics' average media sentiment score of 0.42 beat Beam Therapeutics' score of 0.14 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NTLA or BEAM? Intellia Therapeutics currently has a consensus target price of $61.77, indicating a potential upside of 169.38%. Beam Therapeutics has a consensus target price of $44.18, indicating a potential upside of 69.67%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Intellia Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.80Beam Therapeutics 0 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.46 Do insiders and institutionals hold more shares of NTLA or BEAM? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.0% of Intellia Therapeutics shares are held by insiders. Comparatively, 4.2% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, NTLA or BEAM? Intellia Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. SummaryIntellia Therapeutics beats Beam Therapeutics on 11 of the 19 factors compared between the two stocks. Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14B$3.10B$5.53B$8.47BDividend YieldN/A1.95%4.96%4.06%P/E Ratio-14.6328.16147.2318.90Price / Sales6.08271.191,772.4384.26Price / CashN/A148.4437.1531.47Price / Book2.163.984.954.56Net Income-$132.53M-$43.91M$114.99M$225.32M7 Day Performance-0.99%-0.25%9.02%4.19%1 Month Performance6.16%24.64%15.51%7.96%1 Year Performance3.21%18.99%33.13%15.09% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NTLAIntellia Therapeutics4.493 of 5 stars4.49 / 5 stars$22.07+6.8%$61.77+179.9%-33.3%$2.24B$36.28M-4.12600Analyst ForecastGap UpKYMRKymera Therapeutics1.2577 of 5 stars1.26 / 5 stars$46.08+3.0%$48.67+5.6%+161.5%$2.83B$88.55M-18.36170Insider SellingGap UpREPLReplimune Group4.7644 of 5 stars4.76 / 5 stars$11.13+7.2%$16.20+45.6%-37.0%$760.40MN/A-3.44210Gap UpEDITEditas Medicine4.1726 of 5 stars4.17 / 5 stars$3.95+5.3%$11.22+184.1%-51.1%$325.80M$78.12M-1.88230Analyst ForecastShort Interest ↑News CoverageSGMOSangamo Therapeutics2.1009 of 5 stars2.10 / 5 stars$0.85+4.7%$2.67+214.3%+6.4%$176.65M$176.23M-0.46480Options VolumeNews CoverageEXELExelixis4.4622 of 5 stars4.46 / 5 stars$26.46+0.6%$27.43+3.7%+25.3%$8.02B$2.01B41.341,310Analyst ForecastAnalyst RevisionNews CoverageHALOHalozyme Therapeutics4.7053 of 5 stars4.71 / 5 stars$62.30+2.9%$59.44-4.6%+49.6%$7.89B$829.25M25.74390Analyst DowngradeInsider SellingRGENRepligen4.8885 of 5 stars4.89 / 5 stars$139.99-1.4%$188.38+34.6%-11.9%$7.82B$602.35M559.981,783Gap UpRVMDRevolution Medicines4.0937 of 5 stars4.09 / 5 stars$43.70+4.1%$52.92+21.1%+49.0%$7.30B$11.58M-11.65250Gap UpKRYSKrystal Biotech4.6751 of 5 stars4.68 / 5 stars$201.58+3.0%$196.75-2.4%+52.3%$5.79B$50.70M107.80210Gap Up Related Companies and Tools Related Companies: NTLA Alternatives KYMR Alternatives REPL Alternatives EDIT Alternatives SGMO Alternatives EXEL Alternatives HALO Alternatives RGEN Alternatives RVMD Alternatives KRYS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BEAM) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAM Stock Alerts